Abhijeeth Chandrasekaran
Abhijeeth Chandrasekaran has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Amy Watters
JMI Laboratories, 345 Beaver Kreek Center, North Liberty, USA
3 shared publications- Balasubramanian V
Bugworks Research India Pvt. Ltd. Center for Cellular & Molecular Platforms, National Center for Biological Sciences, GKVK Campus, Bellary Road, Bangalore, India
3 shared publications Claire Sadler
Apconix Ltd. Alderley Park, Alderley Edge, Cheshire, UK
3 shared publicationsDan Sahm
IHMA USA, 2122 Palmer Drive, Schaumburg, USA
3 shared publicationsDhanasekaran Manickam
Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra Jigani Link Road, Bangalore, India
3 shared publicationsDhanashree Pillai
Bugworks Research India Pvt. Ltd. Center for Cellular & Molecular Platforms, National Center for Biological Sciences, GKVK Campus, Bellary Road, Bangalore, India
3 shared publications
Latest Publications
- Open Access
- 28 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- 28 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- Open Access
- 13 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- 13 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- Open Access
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibited a minimum inhibitory concentration (MIC90) of 0.03–2 µg/mL against a global panel of MDR Gram-negative bacteria including Enterobacterales and non-fermenters, Gram-positive bacteria, anaerobes and biothreat pathogens. BWC0977 retains activity against isolates resistant to fluoroquinolones (FQs), carbapenems and colistin and demonstrates efficacy against multiple pathogens in two rodent species with significantly higher drug levels in the epithelial lining fluid of infected lungs. In healthy volunteers, single-ascending doses of BWC0977 administered intravenously (https://clinicaltrials.gov/study/NCT05088421) was found to be safe, well tolerated (primary endpoint) and achieved dose-proportional exposures (secondary endpoint) consistent with modelled data from preclinical studies. Here, we show that BWC0977 has the potential to treat a range of critical-care infections including MDR bacterial pneumonias.
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessBWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibited a minimum inhibitory concentration (MIC90) of 0.03–2 µg/mL against a global panel of MDR Gram-negative bacteria including Enterobacterales and non-fermenters, Gram-positive bacteria, anaerobes and biothreat pathogens. BWC0977 retains activity against isolates resistant to fluoroquinolones (FQs), carbapenems and colistin and demonstrates efficacy against multiple pathogens in two rodent species with significantly higher drug levels in the epithelial lining fluid of infected lungs. In healthy volunteers, single-ascending doses of BWC0977 administered intravenously (https://clinicaltrials.gov/study/NCT05088421) was found to be safe, well tolerated (primary endpoint) and achieved dose-proportional exposures (secondary endpoint) consistent with modelled data from preclinical studies. Here, we show that BWC0977 has the potential to treat a range of critical-care infections including MDR bacterial pneumonias.